Targeted immunotherapies for Graves' thyroidal & orbital diseases

Area of Science:

• Endocrinology
• Immunology
• Pharmacology

Background:

• Graves' hyperthyroidism and Graves' orbitopathy are common autoimmune disorders.
• Current treatments have limitations in efficacy and safety.
• There is a need for therapies targeting specific pathogenic mechanisms.

Purpose of the Study:

• To review the latest developments in targeted immunotherapies for Graves' hyperthyroidism and Graves' orbitopathy.
• To highlight novel therapeutic approaches and their mechanisms of action.

Main Methods:

• Review of recent clinical studies and therapeutic advances.
• Focus on targeted immunotherapies including monoclonal antibodies and small molecule inhibitors.
• Analysis of treatment efficacy and safety profiles.

Main Results:

• Several targeted immunotherapies demonstrate clinical efficacy in early phase studies.
• Rituximab, ATX-GD-59, iscalimab, and K1-70 show potential for Graves' hyperthyroidism.
• Advances in Graves' orbitopathy include mycophenolate, tocilizumab, sirolimus, teprotumumab, linsitinib, and batoclimab, showing promise in various disease aspects.

Conclusions:

• Targeted immunotherapies represent a significant advancement in managing Graves' hyperthyroidism and Graves' orbitopathy.
• These novel therapies offer improved efficacy and safety, targeting specific disease pathways.
• Future therapeutic strategies will focus on optimizing management for better patient outcomes.